AstraZeneca PLC





Market Closed - London S.E. 16:35:25 24/06/2024 BST 5-day change 1st Jan Change
12,478 GBX +0.05% Intraday chart for AstraZeneca PLC +0.40% +17.72%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit RE
G1 Therapeutics' breast cancer drug fails in late-stage trial RE
ASTRAZENECA : Barclays maintains a Buy rating ZD
US FDA approves Roche's drug for a chronic blood disorder RE
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher MT
AstraZeneca Says Truqap With Faslodex Combination Approved in EU for Breast Cancer MT
AstraZeneca's Truqap gets OK from EU for breast cancer form AN
AstraZeneca: EU approval in breast cancer CF
AstraZeneca Wins EU Approval for Breast Cancer Combination Treatment MT
Astrazeneca Says Truqap Plus Faslodex Approved In EU RE
AstraZeneca Signs Mobile Support Collaboration for Breast Cancer Patients MT
Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon... Our Logo
ASTRAZENECA : Goldman Sachs maintains a Buy rating ZD
AstraZeneca plc Updates on the CAPItello-290 Phase III Trial for Truqap Plus Chemotherapy CI
AstraZeneca disappointed by breast cancer drug trial results AN
London follows US bullish trend Our Logo
AstraZeneca: inconclusive trial in breast cancer CF
AstraZeneca's Breast Cancer Combo Fails to Extend Overall Survival in Late-stage Trial MT
UK Stocks-Factors to watch on June 18 RE
Ashtead profit declines; Whitbread sales rise AN
AstraZeneca's breast cancer drug combination fails in late-stage trial RE
AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals DJ
European Equities Close Mixed in Monday Trading; UBS Sued by Russian-Uzbek Billionaire Usmanov MT
Global markets live: AstraZeneca, Apple, Meta, Microsoft, Cisco... Our Logo
AstraZeneca Says FDA Approves Imfinzi to Treat Endometrial Cancer MT
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
157.5 USD
Average target price
174.4 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement